Exelixis Inc
$13.63B- Market cap
- $14.29B
- Debt
- +$399.32M
- Cash
- −$1.06B
Capital structure 97% equity / 3% debt · EV / Revenue 5.87x · EV / EBITDA 14.48x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $14.29B · View financials
Snapshot Sep 8, 2026, 4:00 PM ET
FY 2026 ·
Decision snapshot: EXEL stock price vs TEAM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TEAM's multiple
Needs TEAM P/E.
Implied fair value · at EXEL's multiple
Needs Annual EPS.
Metric by metric
Snapshot Sep 8, 2026, 4:00 PM ET
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXEL FY 2026 (ended Jan 2, 2026) · TEAM FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 5.87x · EV / EBITDA 14.48x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Exelixis Inc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Atlassian Corporation · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.18x
0.93x
Net debt / EBITDA
Leverage against operating earnings
-0.70x
-1.15x
Cash and equivalents
Liquid reserves on the balance sheet
$1.06B
$1.24B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
EXEL vs AMGN
BIOGEN INC.
EXEL vs BIIB
GILEAD SCIENCES, INC.
EXEL vs GILD
INCYTE CORP
EXEL vs INCY
Sarepta Therapeutics, Inc.
EXEL vs SRPT
MICROSOFT CORP
EXEL vs MSFT
ADOBE INC.
EXEL vs ADBE
Salesforce, Inc.
EXEL vs CRM
ORACLE CORP
EXEL vs ORCL
DOCUSIGN, INC.
EXEL vs DOCU
BOX INC
EXEL vs BOX
$399.32M
$989.56M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.